Is VEON a Buy or a Sell? The Bull and Bear Case (2026)

The most optimistic published target on VEON is $100.00, +20.2% from the $83.20 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

The most pessimistic published target is $73.52, -11.6% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks VEON Ltd is worth if the risks below bite instead of the drivers above.

VEON's risk profile is dominated by its geographies. Ukraine remains at war, which threatens Kyivstar's operations, infrastructure and outlook. Pakistan and Bangladesh face political instability, economic stress and, at times, government-ordered network shutdowns that hit revenue. Currency risk is severe: revenue is earned in volatile local currencies while the stock is dollar-denominated, so devaluations can sharply cut reported results and any dividend value. Regulatory, licensing, spectrum and tax regimes in frontier markets can change abruptly and unfavourably. VEON carries substantial debt (about $5.85 billion of total debt against about $2.69 billion of cash per market data) and depends on cash flows from operating subsidiaries that face capital controls and repatriation friction. The value-crystallisation strategy depends on receptive capital markets. Sanctions, security incidents and macro shocks can all move the shares dramatically. Liquidity and disclosure standards may differ from those of developed-market peers, and the ADR adds another layer between investors and the underlying assets. After a roughly 58% three-month rally the stock sits near the ~$87 average analyst target, trading at about 106x trailing earnings (depressed by 2025 losses) and about 10x forward earnings, so a miss on the November 6, 2026 Q3 report could matter more than it did when the shares were cheaper.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding VEON already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

7 analysts cover VEON, with an average target of $86.87 (+4.4% against $83.20) and a split of 4 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the VEON forecast and price target page.

• Revenue (TTM): ~$4.76 billion; Q2 2026 ~$1.27 billion, up ~17% YoY. Reported in US dollars but earned in volatile local currencies.
• Net income (TTM): ~$59 million, held down by losses in the second half of 2025; Q1 and Q2 2026 net income were ~$99 million and ~$122 million.
• P/E (trailing / forward): ~106x trailing (depressed earnings) / ~10x forward on 2027 estimates of ~$8.39 per ADR.
• EV/EBITDA: ~5x on trailing EBITDA of ~$1.85 billion.
• Balance sheet: ~$5.85 billion of debt against ~$2.69 billion of cash; relies on cash from subsidiaries that can face capital controls and repatriation friction.
• Dividend: None currently per market data; any distribution depends on cash upstreaming from emerging-market subsidiaries.
• Market cap: ~$5.75 billion
• Analyst view: Seven analysts, consensus strong buy, average target ~$87, close to the current price.

All figures are approximate as of October 16, 2026. VEON reports in US dollars but earns in local currencies, so results can move sharply with exchange rates and country-specific events. On forward estimates the stock trades near 10x earnings and about 5x EV/EBITDA, still a frontier-market discount, but the ~59% year-to-date rise has narrowed it. Q3 2026 results are due November 6, 2026, with consensus near $1.72 per ADR on ~$1.31 billion of revenue.

Rather than asking whether VEON is a buy in the abstract, it tends to help to answer four questions:

• Thesis: do you believe the bull case above, and is it still true today?
• Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
• Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
• Overlap: check whether you already hold VEON indirectly through an index or sector ETF before adding more.

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

• Bull case breaks if: Emerging-market connectivity growth stalls in the reported numbers rather than in the narrative around them.
• Bear case breaks if: vEON's risk profile is dominated by its geographies fails to materialise over several reporting periods while the drivers keep compounding.
• Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the VEON stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about VEON against your real portfolio and see your actual exposure before deciding.